The U.S. Senate Special Committee on Aging has taken a strong stance on improving drug quality and supply chain integrity, holding a series of hearings and issuing a bipartisan investigative report that directly highlights Valisure’s ongoing collaboration with the U.S. Department of Defense (DoD) on pharmaceutical quality measures.

The Senate Aging Committee Report, released on October 20, 2025 by Chairman Rick Scott (R-FL) and Ranking Member Kirsten Gillibrand (D-NY), titled “Exposing America’s Dangerous Overreliance on Foreign-Made Generic Drugs,” underscored the need for sweeping reform in government drug procurement practices. The report cited Valisure’s quality measures project with the military as a model for enhancing transparency, accountability, and resilience in the nation’s medicine supply.

The recognition follows two recent committee hearings:

• “Prescription for Trouble: Drug Safety, Supply Chains, and the Risk to Aging Americans” (September 17, 2025)
• “Bad Medicine: Closing Loopholes that Kill American Patients” (October 8, 2025)

Both hearings examined the risks posed by substandard and foreign-made generics, with lawmakers emphasizing the importance of independent quality verification. Valisure was honored by multiple mentions in the committee’s report and deeply appreciated all the Senators involved acknowledging the positive potential of the company’s ongoing work with the Department of Defense.

Valisure remains committed to advancing meaningful reforms that strengthen pharmaceutical quality and safeguard public health through transparency, testing, and evidence-based procurement practices.

‍

The U.S. Senate Special Committee on Aging has taken a strong stance on improving drug quality and supply chain integrity, holding a series of hearings and issuing a bipartisan investigative report that directly highlights Valisure’s ongoing collaboration with the U.S. Department of Defense (DoD) on pharmaceutical quality measures.

The Senate Aging Committee Report, released on October 20, 2025 by Chairman Rick Scott (R-FL) and Ranking Member Kirsten Gillibrand (D-NY), titled “Exposing America’s Dangerous Overreliance on Foreign-Made Generic Drugs,” underscored the need for sweeping reform in government drug procurement practices. The report cited Valisure’s quality measures project with the military as a model for enhancing transparency, accountability, and resilience in the nation’s medicine supply.

The recognition follows two recent committee hearings:

• “Prescription for Trouble: Drug Safety, Supply Chains, and the Risk to Aging Americans” (September 17, 2025)
• “Bad Medicine: Closing Loopholes that Kill American Patients” (October 8, 2025)

Both hearings examined the risks posed by substandard and foreign-made generics, with lawmakers emphasizing the importance of independent quality verification. Valisure was honored by multiple mentions in the committee’s report and deeply appreciated all the Senators involved acknowledging the positive potential of the company’s ongoing work with the Department of Defense.

Valisure remains committed to advancing meaningful reforms that strengthen pharmaceutical quality and safeguard public health through transparency, testing, and evidence-based procurement practices.

‍